The immunomodulatory properties of low-level ionizing radiation as a potential treatment for COVID-19’s life-threatening symptoms

Abstract

Public health experts are looking into the current coronavirus outbreak to see if there are any ways to prevent potentially fatal symptoms. Low-Dose Radiotherapy (LD-RT) induces anti-inflammatory cytokine responses that act as a counterweight to pro-inflammatory cytokines, potentially providing therapeutic benefits for COVID-19-related diseases associated with significant morbidity and mortality. This study will look into positive immuno-radiological reactions to see if they are feasible, practicable, and effective in lowering the critical inflammatory condition of the crucial stage COVID-19. This study aims to investigate the use of low-dose lung radiation in bacterial and viral pneumonia, as well as to provide a treatment plan for COVID-19-associated pneumonia. This article discusses the evidence for and against LD-RT theories in COVID-19 patients. The use of LD-RT at various stages of COVID-19 appears to be beneficial, with fewer side effects than other currently being studied treatments.

Immuno-Biochemical Impacts of Gamma Irradiation in Male Rats: A Dose-Response Study

“…However, clinically, low radiation doses are practically the intermediate ones of ranges between .3 to 1.0 Gy, applied as single radiation doses for managing degenerative, benign, and inflammatory disorders. 25,26 NO is a biologically active molecule involved in several physiological and pathological reactions in the body. 27 In Figure 3.…”

“…However, clinically, low radiation doses are practically the intermediate ones of ranges between .3 to 1.0 Gy, applied as single radiation doses for managing degenerative, benign, and inflammatory disorders. 25,26…”

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

“…respiratory distress syndrome (ARDS) [11], a potentially life-threatening condition [12]. Advanced stages of COVID-19 may culminate in ARDS [11], characterized by severe lung inflammation [13], culminating in respiratory failure [14].…”